Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference

Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic and ophthalmic diseases with significant unmet medical needs, announced today that Oculis’ management will participate in a fireside chat at the Piper Sandler Virtual Ophthalmology Conference. The Company will provide an overview and update of its innovative current late-stage portfolio. Key highlights include: Privosegtor , a novel neuroprotective candidate which received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) and Priority Medicines (PRIME) designation from the European Medicines Agency (EMA) for optic neuritis (ON), in the PIONEER registrational program to address unmet needs for two optic neuropathies targeting an estimated potential market opportunity of $7B+ in the U.S. alone, and Licaminlimab , a topical anti-TNFα being evaluated in the PREDICT-1 registrational trial as the first genotype-based precision medicine approach in dry eye disease (DED). With a strong balance sheet and advanced pipeline, Oculis is well positioned to deliver value-driving milestones across our targeted registrational programs, focusing on fulfilling its mission to save sight and improve eye care with groundbreaking treatments.

Piper Sandler Virtual Ophthalmology Conference Date: July 10, 9:30am ET Location: Miami, FL Format: Fireside chat Presenter: Sylvia Cheung, CFO

The Company will be available for one-on-one meetings during the conference. Interested investors should contact their Piper Sandler & Co. (PSC) sales representative for registration information or to request a meeting.